Pharmaceutical Co-crystals: A Tool to Enhance Drug Solubility and Bioavailability

Abstract

Poor solubility of drugs remains a significant challenge in pharmaceutical development, leading to reduced bioavailability and compromised therapeutic efficacy. Pharmaceutical co-crystals have become a viable means of getting around these solubility restrictions and improving the bioavailability of medications that aren't very soluble. Co-crystals are multi-component crystalline structures made up of one or more coformers and an Active Pharmaceutical Ingredient (API) that are bound together by non-covalent bonds. Without changing the API's structure chemically, these interactions produce a distinct crystal lattice that modifies its physical characteristics. The review highlights the principles behind cocrystal formation, including the selection of suitable coformers based on hydrogen bonding, π-π stacking, and other intermolecular forces. Rational cocrystal design and screening techniques are discussed, emphasizing the applications of pharmaceutical co-crystals as a strategy for enhancing the bioavailability and solubility of drugs that are poorly soluble. Furthermore, the review explores various methods for cocrystal preparation and characterization techniques used to confirm cocrystal formation and assess the purity, stability, and performance of the Co-crystals. In conclusion, the potential of co-crystals as an innovative and versatile tool to enhance drug solubility and bioavailability, ultimately advancing the field of pharmaceutical sciences and improving patient treatment options.